|
ATCC
human umbilical vein endothelial cells huvecs Human Umbilical Vein Endothelial Cells Huvecs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human/pmc13676988-271-0-17 Average 99 stars, based on 1 article reviews
human umbilical vein endothelial cells huvecs - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
Innoprot Inc
mouse aortic endothelial cells Mouse Aortic Endothelial Cells, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Mouse+Aortic+Endothelial+Cells/custom%40p10427%4042979299 Average 94 stars, based on 1 article reviews
mouse aortic endothelial cells - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Cell Applications Inc
endothelial cell growth medium v2 Endothelial Cell Growth Medium V2, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Human+Endothelial+Cell+Media+v2/pm42929833-69-17-22 Average 94 stars, based on 1 article reviews
endothelial cell growth medium v2 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
PromoCell
human dermal lymphatic endothelial cells Human Dermal Lymphatic Endothelial Cells, supplied by PromoCell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Human+Dermal+Lymphatic+Endothelial+Cells+(HDLEC)+adult+donor/pm42929833-69-0-6 Average 94 stars, based on 1 article reviews
human dermal lymphatic endothelial cells - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
PromoCell
endothelial basal medium ecbm mv2 Endothelial Basal Medium Ecbm Mv2, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Endothelial+Cell+Basal+Medium+MV+2/pm42927198-185-13-17 Average 95 stars, based on 1 article reviews
endothelial basal medium ecbm mv2 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
PromoCell
human umbilical vein endothelial cells huvecs ![]() Human Umbilical Vein Endothelial Cells Huvecs, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Human+Umbilical+Vein+Endothelial+Cells+(HUVEC)+single+donor/pmc13686634-201-0-9 Average 98 stars, based on 1 article reviews
human umbilical vein endothelial cells huvecs - by Bioz Stars,
2026-11
98/100 stars
|
Buy from Supplier |
|
PromoCell
endothelial growth medium 2 ![]() Endothelial Growth Medium 2, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Endothelial+Cell+Growth+Medium+2/pmc13686634-201-20-24 Average 98 stars, based on 1 article reviews
endothelial growth medium 2 - by Bioz Stars,
2026-11
98/100 stars
|
Buy from Supplier |
|
PromoCell
lymphatic endothelial cells lec ![]() Lymphatic Endothelial Cells Lec, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Human+Dermal+Lymphatic+Endothelial+Cells+(HDLEC)+juvenile+foreskin/pmc13682602-80-1-5 Average 96 stars, based on 1 article reviews
lymphatic endothelial cells lec - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
ATCC
c166 mouse endothelial cells ![]() C166 Mouse Endothelial Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/C166/pmc13676988-271-9-17 Average 95 stars, based on 1 article reviews
c166 mouse endothelial cells - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
PromoCell
endothelial cell medium ![]() Endothelial Cell Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/endothelial+cells/Endothelial+Cell+Basal+Medium+MV+2/pm42883398-63-5-8 Average 95 stars, based on 1 article reviews
endothelial cell medium - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: ( A ) Immunoblot for Shc and SUMO2 expression in HUVECs following p66Shc knockdown (si-p66Shc) and SUMO2 overexpression (Ad-HA-SUMO2). ( B, C ) Quantification of ROS (MitoSOX fluorescence) in HUVECs from A. *p<0.05; n=24–32; Student’s t -test. ( D ) Quantification of ROS in HUVECs following p66Shc knockdown (si-p66Shc) and SUMO2 overexpression (Ad-HA-SUMO2). ***p<0.001, p<0.05; n=10–15; One-way ANOVA. Data represents mean ± SEM. Immunoblots are representative of at least three independent experiments. GC, scrambled siRNA used as control; HUVECs, human umbilical vein endothelial cells. Figure 1—source data 1. PDF file containing original western blots for . Figure 1—source data 2. Original files for western blot analysis displayed in .
Article Snippet:
Techniques: Western Blot, Expressing, Knockdown, Over Expression, Fluorescence, Control, Analysis
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: ( A ) Immunoblot for sumoylated p66Shc in HEK-293 cells overexpressing SUMO2 (HA-SUMO2) and p66Shc (Flag-p66Shc). ( B ) Immunoblot for p66Shc sumoylation in HEK-293 cells overexpressing SUMO2 (HA-SUMO2) and p66Shc (Flag-p66Shc) with or without overexpression of Ubc9 (HA-Ubc9) and SENP1 (Flag-SENP1). ( C ) Immunoblot for sumoylation of p66Shc in human umbilical vein endothelial cells (HUVECs) overexpressing SUMO2 (Ad-HA-SUMO2) or p66Shc (Ad-Flag-p66Shc). ( D ) Immunoblot for p66Shc sumoylation in HUVEC cells overexpressing SUMO2 (Ad-HA-SUMO2) or p66Shc (Ad-Flag-p66Shc) in the presence or absence of anacardic acid. Quantification of SUMO2-p66Shc from immunoblot of D. One-way ANOVA, followed by Tukey’s post-hoc analysis, n=4 *p<0.05, **p<0.01. ( F ) Immunoblot for sumoylated recombinant p66Shc in the presence of absence of Ubc9. Immunoblots are representative of at least three independent experiments. Data represents mean ± SEM. Ad-Lac Z was used as an adenoviral control to compensate for the difference in MOI among the groups. Figure 2—source data 1. PDF file containing original western blots for . Figure 2—source data 2. Original files for western blot analysis displayed in .
Article Snippet:
Techniques: Western Blot, Over Expression, Analysis, Recombinant, Control
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: Immunoblot of human umbilical vein endothelial cells (HUVECs) transduced with wild-type p66Shc (Ad-Flag-p66ShcWT) and SUMO2 (Ad-HA-SUMO2) at the indicated concentrations. Immunoblots are representative of at least three independent experiments. Figure 2—figure supplement 1—source data 1. PDF file containing original western blots for . Figure 2—figure supplement 1—source data 2. Original files for western blot analysis displayed in .
Article Snippet:
Techniques: Western Blot, Transduction, Analysis
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: ( A ) Modular structure of p66Shc showing conserved lysine-81 in the CH2 domain. ( B ) Tandem mass spectrometry of in vitro SUMO2ylated recombinant p66Shc. ( C ) Immunoblot showing sumoylation of p66Shc in HEK-293 cells overexpressing p66ShcWT (Flag-p66ShcWT) or p66ShcK81R (Flag-p66ShcK81R) with and without SUMO2 (HA-SUMO2). ( D ) Immunoblot showing sumoylation of p66Shc in human umbilical vein endothelial cells (HUVECs) overexpressing p66ShcWT (Ad-Flag-p66ShcWT) or p66ShcK81R (Ad-p66ShcK81R) with and without SUMO2 (Ad-HA-SUMO2). ( E ) Immunoblot for sumoylation of recombinant p66ShcWT or p66ShcK81R. ( F ) Immunoprecipitation of SUMO2-p66Shc using SUMO2-p66ShcK81 antibody or the matching IgG control in HUVECs followed by immunoblotting with SUMO2-p66ShcK81 antibody showing endogenous SUMO2ylation of p66Shc (left-side panel, the high-intensity IgG signal was masked with a tape which appears as a white strip). Immunoblotting with Shc antibody in whole-cell lysate (right-side panel). Immunoblots are representative of at least three independent experiments. CH2, collagen homology 2; PTB, phosphotyrosine binding; CH1, collagen homology 1; SH2, Src homology 2. Figure 3—source data 1. PDF file containing original western blots for . Figure 3—source data 2. Original files for western blot analysis displayed in . Figure 3—source data 3. PDF file containing original western blots for . Figure 3—source data 4. Original files for western blot analysis displayed in . Figure 3—source data 5. PDF file containing original western blots for . Figure 3—source data 6. Original files for western blot analysis displayed in . Figure 3—source data 7. PDF file containing original western blots for . Figure 3—source data 8. Original files for western blot analysis displayed in .
Article Snippet:
Techniques: Mass Spectrometry, In Vitro, Recombinant, Western Blot, Immunoprecipitation, Control, Stripping Membranes, Binding Assay, Analysis
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: ( A ) Immunoblot for p66ShcS36 phosphorylation in HEK-293 cells overexpressing SUMO2 (HA-SUMO2) and p66ShcWT (Flag-p66ShcWT). ( B ) Quantification of p66ShcS36 phosphorylation from A. *p<0.05; n=6; one-way ANOVA. ( C ) Immunoblot for p66ShcS36 phosphorylation in human umbilical vein endothelial cells (HUVECs) overexpressing SUMO2 (Ad-HA-SUMO2) or p66ShcWT (Ad-Flag-p66ShcWT). ( D ) Quantification of p66ShcS36 phosphorylation from C. *p<0.05; n=8; one-way ANOVA. ( E ) Immunoblot for p66ShcS36 phosphorylation in HUVECs expressing SUMO2 (Ad-HA-SUMO2) and p66ShcWT (Ad-Flag-p66ShcWT) or p66ShcK81R (Ad-Flag-p66ShcK81R). ( F ) Quantification of p66ShcS36 phosphorylation from E. *p<0.05, **p<0.01; n=11; two-way ANOVA. Immunoblots were quantified with iBright image analysis software. Data represents mean ± SEM. Immunoblots are representative of at least three independent experiments. Figure 4—source data 1. PDF file containing original western blots for . Figure 4—source data 2. Original files for western blot analysis displayed in . Figure 4—source data 3. PDF file containing original western blots for . Figure 4—source data 4. Original files for western blot analysis displayed in . Figure 4—source data 5. PDF file containing original western blots for . Figure 4—source data 6. Original files for western blot analysis displayed in .
Article Snippet:
Techniques: Western Blot, Phospho-proteomics, Expressing, Analysis, Software
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: ( A ) Immunoblot for p66ShcWT in whole-cell lysates or the mitochondrial fraction of human umbilical vein endothelial cells (HUVECs) ectopically expressing SUMO2 (Ad-HA-SUMO2) and p66ShcWT (Ad-Flag-p66ShcWT). ( B ) Quantification of the relative abundance of p66Shc in the mitochondria from A. **p<0.01, ****p<0.0001; n=5; one-way ANOVA. ( C ) Immunoblot for p66Shc in whole-cell lysates or the mitochondrial fraction of HUVECs ectopically expressing SUMO2 (Ad-HA-SUMO2) and p66ShcWT Ad-Flag-p66ShcWT or p66ShcK81R (Ad-Flag-p66ShcK81R). ( D ) Quantification of relative abundance of p66Shc in the mitochondria from C. *p<0.05, **p<0.01; n=7; two-way ANOVA. Data represents mean ± SEM. Immunoblots are representative of at least three independent experiments. Figure 5—source data 1. PDF file containing original western blots for . Figure 5—source data 2. PDF file containing original western blots for . Figure 5—source data 3. PDF file containing original western blots for . Figure 5—source data 4. Original files for western blot analysis displayed in .
Article Snippet:
Techniques: Western Blot, Expressing, Analysis
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: ( A ) Immunoblot showing oxidized-LDL (o-LDL)-induced changes in small ubiquitin-like modifier 2/3 (SUMO2/3)-conjugated proteins in human umbilical vein endothelial cells (HUVECs) with and without SUMO2. ( B ) Graph showing serum cholesterol-level in wild-type, Ldlr -/- mice on a high fat diet, and Shc1 K81R mice on a high fat diet (n=4/group). One-way ANOVA, ****p<0.0001. Graphs showing % contraction following induction of endothelium-dependent relaxation ( C ) and endothelium-independent relaxation ( D ) in aortic rings from male wild-type mice, (n=14 rings from 5 mice), Ldlr -/- mice on a high fat diet (n=18 rings from 6 mice) and Ldlr - /- :: Shc1 K81R mice on a high fat diet (n=12 rings from 6 mice). Two-way ANOVA. ***p<0.001. ( E ) Representative images showing the level of 8-OHdG in aortic section of Ldlr -/- mice on a high fat diet (n=6 mice) and Ldlr -/- :: Shc1 K81R mice on a high fat diet (n=6 mice) and their ( F ) quantification. One-way ANOVA. *p<0.05. HFD, high fat diet; Ach, acetylcholine; SNP, sodium nitroprusside; PE, Phenylephrine; 8-OHdG, 8 hydroxy deoxyguanosine. Data represents mean ± SEM. Figure 7—source data 1. Source data for immunoblots in . Figure 7—source data 2. Original datasets for .
Article Snippet:
Techniques: Western Blot, Ubiquitin Proteomics
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: ( A ) Representative immunoblots of endothelial cell lysate expressing Flag-p66ShcWT, Flag-p66ShcK81R, and HA-SUMO2 (n=3 shown, n=6 performed). ( B ) Bubble chart representation of all the regulatory pathways impacted by SUMO2-p66Shc in endothelial cells, rescued by p66ShcK81R. Pathway enrichment analysis was performed using R-based Reactome pathway analysis and visualization packages on differential protein expression data obtained from HUVECs expressing SUMO2-p66ShcWT or SUMO2-p66ShcK81R compared with Ad-LacZ controls (n=6). Figure 8—figure supplement 1—source data 1. PDF file containing original western blots for . Figure 8—figure supplement 1—source data 2. Original files for western blot analysis displayed in .
Article Snippet:
Techniques: Western Blot, Expressing, Analysis
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: ( A, B ) Principal component analysis (PCA) of proteins expressed in endothelial cells expressing SUMO2+p66ShcWT and SUMO2+p66ShcK81R. ( C, D ) Bar chart presentation of key regulatory pathways differentially affected by small ubiquitin-like modifier 2 (SUMO2)-p66ShcWT ( C ) and SUMO2-p66ShcK81R ( D ) in endothelial cells. The protein expression data (fold change) were obtained from human umbilical vein endothelial cells (HUVECs) expressing SUMO2 with p66ShcWT or p66ShcK81R compared to those expressing Ad-Lac Z. Pathway enrichment analysis ( B ) was performed using R-based bioinformatics tools, including PROGENy/decoupleR pathway activity inference and visualization packages. Differentially regulated pathways associated with senescence, mitochondrial dysfunction, apoptosis signaling, and angiogenesis are shown. Data were derived from a sample size of n=6.
Article Snippet:
Techniques: Analysis, Expressing, Ubiquitin Proteomics, Activity Assay, Derivative Assay
Journal: eLife
Article Title: p66Shc mediates SUMO2-induced endothelial dysfunction
doi: 10.7554/eLife.106344
Figure Lengend Snippet: Amplex Red assay performed in HUVECs with and without knockdown of p66Shc expressing SUMO2 (Ad-SUMO2) or a control virus (Ad-LacZ).
Article Snippet:
Techniques: Amplex Red Assay, Knockdown, Expressing, Control, Virus
Journal: Molecular Oncology
Article Title: Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers
doi: 10.1002/1878-0261.70343
Figure Lengend Snippet: Anti‐LVRF antibodies inhibit lymphangiogenesis, decrease tumor spheroid invasion and metabolism. (A) Quantification of lymphatic endothelial cell (LEC) sprouting in a 3D bead assay under control conditions, stimulation with recombinant LVRF (200 ng·mL −1 ), or LVRF in the presence of anti‐LVRF antibodies (100 μg·mL −1 ) ( n = 3). (B) Representative images of 786‐O clear cell renal cell carcinoma (ccRCC) spheroids cultured in a 3D invasion assay under control conditions or treated with antibodies (30 or 300 μg·mL −1 ), scale bars, 1 mm. Quantification of spheroid invasion area (C) ( n = 4–18), and cell metabolism activity measured by CellTiter‐Glo assay, expressed as percentage of control following treatment with increasing concentrations of antibodies (10–300 μg·mL −1 ) (D) ( n = 4–18). Data represent mean ± SEM and were analyzed by one‐way ANOVA with Dunnett's T3 multiple comparisons test. * P < 0.05, ** P < 0.01, *** P < 0.001.
Article Snippet: The
Techniques: Control, Recombinant, Spheroids, Cell Culture, Invasion Assay, Activity Assay, Glo Assay